EPI-321
Asset
AAV-delivered epigenetic modulation silences DUX4 expression without altering the underlying DNA sequence.
- Stage
- Phase 2
- Modality
- Gene therapy
- Target
- Epigenetic regulation of gene expression
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Facioscapulohumeral muscular dystrophy
Phase 2, epicrispr.com, 10 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets1
- Competitors11
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.